We read with interest the study by Lee et al 1 showing no difference in risk of hepatocellular carcinoma (HCC) and mortality or liver transplantation (LT) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV). We searched Medline, Embase, Scopus, Web of Science and Cochrane database to identify studies comparing TDF and ETV for prevention of HCC and mortality or LT in CHB patients. A total of 11 studies with 70 860 patients (TDF=20 105 and ETV=50 755) were included in this meta-analysis. We used adjusted HR (aHR) when reported and calculated risk ratios (RR) when adjusted effect sizes were not available. These were pooled separately using random effects model. Six studies compared TDF and ETV in propensity score (PS) matched cohorts (in addition to entire cohorts) which were created by matching two groups based on several variables (table 1) to reduce risk of bias.1–6 We …

中文翻译：

---

替诺福韦与恩替卡韦在预防慢性乙型肝炎患者肝细胞癌和死亡率方面的比较

我们饶有兴趣地阅读了 Lee 等人 1 的研究，该研究表明，在接受富马酸替诺福韦酯 (TDF) 与恩替卡韦 (ETV) 治疗的慢性乙型肝炎 (CHB) 患者中，肝细胞癌 (HCC) 和死亡率或肝移植 (LT) 的风险没有差异）。我们检索了 Medline、Embase、Scopus、Web of Science 和 Cochrane 数据库，以确定比较 TDF 和 ETV 预防 CHB 患者 HCC 和死亡率或 LT 的研究。该荟萃分析共纳入了 11 项研究，涉及 70 860 名患者（TDF=20 105 和 ETV=50 755）。我们在报告时使用调整后的 HR (aHR)，并在调整后的效应量不可用时计算风险比 (RR)。使用随机效应模型将这些单独合并。